0 0 0
This online shop is using cookies to give you the best shopping experience. Thereby for example the session information or language setting are stored on your computer. Without cookies the range of the online shop's functionality is limited. If you don't agree, please click here.

Sommer, Zochodne Case Studies in Neurological Pain

ISBN: 978-0-521-69526-8

Edition: 1st Ed.

Publication date: November 2012

Cover: Softcover

Pages: 148 p.

Illustrations: 158 ill.

Publisher: Cambridge

Delivery times, dependent on availability and publisher: between 2 and 14 days from when you complete the order.

Description

Pain is one of the most common symptoms of neurological disease and its appropriate management is essential to the effective care of patients. Neurological disorders differ in their specific pain phenotype, mechanisms and therapy. Case Studies in Neurological Pain addresses the specific pain issues, treatment and pathophysiology in patients with a wide spectrum of neurological disease. Clinical case studies have long been recognized as a useful adjunct to problem-based learning and continuing professional development. They emphasize the need for clinical reasoning, integrative thinking, problem-solving, communication, teamwork and self-directed learning – all desirable generic skills for health care professionals. Presenting real-life cases – covering conditions including diabetic and idiopathic polyneuropathies, focal neuropathies, multiple sclerosis and headache disorders – this book provides neurologists, neurosurgeons, pain clinic specialists and primary care physicians with an understanding of problems encountered in neurological practice. There are also chapters on mechanisms of neurological pain and new treatment guidelines.

  • Includes recommended treatment plans to aid quick and accurate treatment
  • Real-life cases facilitate understanding of the patient´s problems more accurately than data from clinical trials
  • Discusses mechanisms of pain and therapeutic challenges to guide researchers and industry in their approach to new therapies